Placeholder

Letter from the Editor

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1484. Category: .

Product Description

Business not as usual. This month’s Forum — Virtual Pharma: Cheaper, Faster, but Doable? — hits a chord particularly close to home to us at PharmaVOICE.
Over the past eight years, we’ve witnessed more than just a few companies coming to a virtual reality. In fact, Stan Bernard of Bernard and Associates says many of the larger, established pharma companies have been transitioning to a virtual model for years, particularly since the late 1990s. He says almost every core and supporting pharmaceutical function can be and has been outsourced, including distribution, manufacturing, clinical development, and significant parts of sales and marketing. The last bastion of in-house functionality, product discovery, has been increasingly outsourced to biotechnology companies and other research entities. With increasing competitive and cost pressures, progressive large and small pharma companies are strategically transforming to more…

FEEDBACK